Amryt Pharma plc logo
Amryt Pharma plc AMYT

Annual report 2021
added 12-23-2023

report update icon

Amryt Pharma plc Income Statement 2011-2026 | AMYT

Annual Income Statement Amryt Pharma plc

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

2.55 B 449 M - - - - - - - - -

Shares

236 M 31.7 M - - - - - - - - -

Historical Prices

10.8 14.2 - - - - - - - - -

Net Income

1 M -105 M -65.5 M -29.5 M -31.4 M -8.21 M -39.7 M -2.56 M -2.12 M -826 K -3.06 M

Revenue

223 M 183 M 58.1 M 17.1 M 15.3 M 1.42 M - - - - -

Cost of Revenue

106 M 119 M 38.7 M 6.27 M - - - - - - -

Gross Profit

116 M 63.6 M 19.4 M 10.8 M 8.88 M 805 K - - - - -

Operating Income

-38.6 M -46.5 M -50.5 M -18 M - - - - - - -

EBITDA

-38.6 M -46.5 M -50.5 M -18 M -16.7 M -5.95 M 33.3 M -2.93 M -202 K -275 K -281 K

Operating Expenses

- 109 M 52.2 M 27.9 M 25.9 M 6.95 M - - - - -

General and Administrative Expenses

92 M - 841 K 17.6 M 13.3 M 4.49 M 3.2 M 2.47 M 1.47 M 275 K 281 K

All numbers in USD currency

Quarterly Income Statement Amryt Pharma plc

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

All numbers in USD currency

The income statement is one of the three key financial reports of a company Amryt Pharma plc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Precigen Precigen
PGEN
$ 3.1 -0.96 % $ 758 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 220.9 2.49 % $ 5 B danmarkDanmark
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.57 1.77 % $ 915 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.33 0.76 % $ 339 M britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
ProQR Therapeutics N.V. ProQR Therapeutics N.V.
PRQR
$ 1.58 6.04 % $ 99.5 M niderlandNiderland
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 8.31 1.59 % $ 111 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 47.09 1.42 % $ 4.23 B schweizSchweiz
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.53 5.1 % $ 868 M canadaCanada
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
$ 4.22 -0.47 % $ 582 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA